



Rabbit (polyclonal) Anti-Tau [pT²¹⁷] Phosphospecific Antibody, Unconjugated

PRODUCT ANALYSIS SHEET

Catalog Number/Size:	44-744 (10 blot size)
Lot Number:	See product label
Volume/Concentration:	See product label
Form of Antibody:	Rabbit polyclonal immunoglobulins in phosphate buffer, pH 7.4, with 1.0 mg/mL BSA (IgG, protease free) as a carrier.
Preservative:	0.05% sodium azide (Caution: sodium azide is a poisonous and hazardous substance. Handle with care and dispose of properly.)
Purification:	Purified from rabbit serum by sequential epitope-specific chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated tau. The final product is generated by affinity chromatography using a tau-derived peptide that is phosphorylated at threonine 217.
Immunogen:	The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human tau that contains threonine 217.
Specificity:	<p>Phosphorylation site-specific antibody selective for the phosphorylated form of human tau containing a phosphate on threonine 217. Tau is a neuronal microtubule-associated protein found predominantly on axons. The function of tau is to promote tubulin polymerization and stabilize microtubules, but it also serves to link certain signaling pathways to the cytoskeleton. Tau phosphorylation regulates both normal and pathological functions of this protein. Tau, in its hyperphosphorylated form, is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer's disease (AD) brain. Hyperphosphorylation impairs the microtubule binding function of tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Hyperphosphorylated tau is also found in a range of other central nervous system disorders. Numerous serine/threonine kinases, including GSK-3β, PKA, PKC, CDK5, stress-activated protein kinases (SAPKs) and casein kinase II can phosphorylate tau.</p> <p>This antibody reacts with human tau phosphorylated at threonine 217. The peptide sequence used to generate the phosphorylation state specific antibody to the threonine 217 site of human tau, is also present in mouse and rat.</p>
Applications:	The antibody has been used for Western blot applications.
Suggested Working Dilutions:	For Western blotting, 0.1-1.0 μ g of antibody/mL in blotting buffer is recommended. At 0.75 μ g/mL, the dilution provides 100 mL working solution, which at 10 mL/blot allows 10 blots to be performed. The optimal antibody concentration should be determined for each specific application.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com
This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44744

(Rev 11/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Storage: Store at -80°C . Upon initial thawing, apportion into working aliquots and store at -80°C . Avoid repeated freeze-thaw cycles to prevent denaturing the antibody.

Expiration Date: Expires one year from date of receipt when stored as instructed.

References:

Liu, F., et al. (2002) Involvement of aberrant glycosylation in phosphorylation of tau by cdk 5 and GSK-3 beta. *FEBS Lett.* 530(1-3):209-214 (cites the use of this antibody).

Alonso, A., et al. (2001) Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and *in vitro* phosphorylation into the disease-like protein. *J. Biol. Chem.* 276:37967-37973 (cites the use of this antibody).

Jenkins, S.M., et al. (2000) Modulation of tau phosphorylation and intracellular localization by cellular stress. *Biochem. J.* 345:263-270.

Tesseur, I., et al. (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. *Am. J. Pathol.* 156(3):951-964.

Takahashi, M., et al. (2000) Distribution of tau protein kinase I/glycogen synthase kinase-3beta, phosphatases 2A and 2B, and phosphorylated tau in the developing rat brain. *Brain Res.* 857:193-206.

Gong, C.X., et al. (2000) Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. *J. Biol. Chem.* 275:5535-5544.


Mandelkow, E. (1999) Alzheimer's disease. The tangled tale of tau. *Nature* 402(6762):588-589.

Davis, P.K. and G.V. Johnson (1999) The microtubule binding of Tau and high molecular weight tau in apoptotic PC12 cells is impaired because of altered phosphorylation. *J. Biol. Chem.* 274:35686-35692.

Alvarez, A., et al. (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. *FEBS Lett.* 459:421-426.

Sontag, E., et al. (1999) Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies. *J. Biol. Chem.* 274:25490-25498.

Haque, N., et al. (1999) Regulation of expression, phosphorylation and biological activity of tau during differentiation in SY5Y cells. *Brain Res.* 838(1-2):69-77.



a b c d

SF-9 cell extracts expressing human four repeat were resolved by SDS-PAGE on a 10% Tris-glycine gel. The proteins were transferred to nitrocellulose. Membranes were incubated with $0.50\ \mu\text{g}/\text{mL}$ anti-phospho tau [pT²¹⁷], following prior incubation in the absence (a) or presence of the peptide immunogen (b), the non-phosphopeptide corresponding to the tau phosphopeptide (c), or a generic [pT] peptide (d). After washing, membranes were incubated with goat F(ab')₂ anti-rabbit IgG alkaline phosphatase (ALI4405) and bands were detected using the Tropix WesternStar™ detection method.

The data show that only the phosphopeptide corresponding to this site blocks the antibody signal, illustrating the specificity of the anti-tau [pT²¹⁷] antibody for this phosphorylation site.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44744

(Rev 11/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Western Blotting Procedure

1. Lyse approximately 10^7 cells in 0.5 mL of ice cold Cell Lysis Buffer (formulation provided below). This buffer, a modified RIPA buffer, is suitable for recovery of most proteins, including membrane receptors, cytoskeletal-associated proteins, and soluble proteins. This cell lysis buffer formulation is available as a separate product which requires supplementation with protease inhibitors immediately prior to use (Invitrogen catalog number FNN0011). Other cell lysis buffer formulations, such as Laemmli sample buffer and Triton-X 100 buffer, are also compatible with this procedure. Additional optimization of the cell stimulation protocol and cell lysis procedure may be required for each specific application.
2. Remove the cellular debris by centrifuging the lysates at 14,000 x g for 10 minutes. Alternatively, lysates may be ultracentrifuged at 100,000 x g for 30 minutes for greater clarification.
3. Carefully decant the clarified cell lysates into clean tubes and determine the protein concentration using a suitable method, such as the Bradford assay. Polypropylene tubes are recommended for storing cell lysates.
4. React an aliquot of the lysate with an equal volume of 2x Laemmli Sample Buffer (125 mM Tris, pH 6.8, 10% glycerol, 10% SDS, 0.006% bromophenol blue, and 130 mM dithiothreitol [DTT]) and boil the mixture for 90 seconds at 100°C.
5. Load 10-30 µg of the cell lysate into the wells of an appropriate single percentage or gradient minigel and resolve the proteins by SDS-PAGE.
6. In preparation for the Western transfer, cut a piece of nitrocellulose slightly larger than the gel.
7. Soak the membrane, 2 pieces of Whatman paper, and Western apparatus sponges in transfer buffer (formulation provided below) for 2 minutes.
8. Assemble the gel and membrane into the sandwich apparatus.
9. Transfer the proteins at 140 mA for 60-90 minutes at room temperature.
10. Following the transfer, rinse the membrane with Tris buffered saline for 2 minutes.
11. Block the membrane with blocking buffer (formulation provided below) overnight at 4°C.
12. Incubate the blocked blot with primary antibody at a concentration of 0.1-1.0 µg/mL in Tris buffered saline supplemented with 1% BSA and 0.1% Tween 20 for 2 hours at room temperature.
13. Wash the blot with several changes of Tris buffered saline supplemented with 0.1% Tween 20.
14. Detect the antibody band using an appropriate secondary antibody, such as goat F(ab')₂ anti-rabbit IgG alkaline phosphatase conjugate (catalog number ALI4405) or goat F(ab')₂ anti-rabbit IgG horseradish peroxidase conjugate (catalog number ALI4404) in conjunction with your chemiluminescence reagents and instrumentation.

Cell Lysis Buffer

Formulation:

10 mM Tris, pH 7.4
100 mM NaCl
1 mM EDTA
1 mM EGTA
1 mM NaF
20 mM Na₄P₂O₇
2 mM Na₃VO₄
0.1% SDS
0.5% sodium deoxycholate
1% Triton-X 100
10% glycerol
1 mM PMSF (made from a
0.3 M stock in DMSO)
or 1 mM AEBSF (water
soluble version of PMSF)
60 µg/mL aprotinin
10 µg/mL leupeptin
1 µg/mL pepstatin
(alternatively, protease inhibitor cocktail such
as Sigma catalog number P2714 may be used)

Transfer Buffer

Formulation:

2.4 gm Tris base
14.2 gm glycine
200 mL methanol
Q.S. to 1 liter, then add
1 mL 10% SDS.
Cool to 4°C prior to use.

Tris Buffered Saline

Formulation:

20 mM Tris-HCl, pH 7.4
0.9% NaCl

Blocking Buffer

Formulation:

100 mL Tris buffered saline
4 gm BSA
0.1 mL Tween 20

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com
This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44744

(Rev 11/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

Peptide Competition Experiment

To demonstrate the specificity of a Phosphorylation Site Specific Antibody, we recommend the following peptide competition experiment which uses our control peptides. These control peptides have the sequences of the phosphopeptide immunogen used to raise the antibody and the corresponding non-phosphorylated peptide. In the competition experiment, 200-500 fold molar excess of the phosphorylated and non-phosphorylated peptides are pre-incubated with aliquots of the antibody prior to use in immunoassay procedures.

A sample calculation for the determination of the 200 fold molar excess of peptide to antibody is presented below. The following assumptions have been made:

- The molecular mass of an IgG molecule is 150,000 daltons.
- Each mole of antibody binds two moles of peptide.
- The Phosphorylation Site Specific Antibody is used at a concentration of 0.5 µg/mL.

The optimal antibody concentration for use in peptide competition experiments is below saturating as determined by previous experiments in your system. If an optimal concentration has not been determined, it is suggested that the concentration provided on the antibody Product Analysis Sheet be used. A final antibody concentration of 0.5 µg/mL is satisfactory for most applications.

The molarity of the 0.5 µg/mL antibody solution is:

$$(0.5 \mu\text{g/mL})(1000 \text{ mL/L}) / (150,000 \mu\text{g}/\mu\text{mole}) = 0.00333 \mu\text{M}.$$

Because each mole of antibody binds two moles of peptide, 0.5 µg/mL antibody can bind 0.00667 µM of peptide.

A 200 fold molar excess of peptide is $(200)(0.00667 \mu\text{M}) = 1.334 \mu\text{M}$.

The following procedure describes peptide competition experiments using antibody at a concentration of 0.5 µg/mL and a 200 fold molar excess of peptides based on the calculation above, in a total volume of 2 mL.

Procedure:

1. Prepare three identical test samples, such as identical nitrocellulose or PVDF strips with transferred protein. The test samples should be blocked with BSA or non-fat dried milk in a buffer compatible with an antibody based detection method, such as Tris buffered saline or phosphate buffered saline.
2. Slowly thaw the Phosphorylation Site Specific Antibody on ice.
3. Prepare 3 mL of a 2x (1 µg/mL) antibody stock solution in a buffer appropriate for the application. Suggested buffer formulations are TBS or PBS supplemented with blocking protein such as BSA or non-fat dried milk.
4. Apportion the unused Phosphorylation Site Specific Antibody into working aliquots and store at -80°C for future use.
5. The lyophilized control peptides should be warmed to room temperature, ideally under desiccation.
6. Reconstitute each of the control peptides to a concentration of 100 µM using nanopure water at room temperature. As indicated on the peptide labels, each vial contains 0.1 mg. For a peptide with a molecular mass of 1500, reconstitution with 0.67 mL water yields a solution with a concentration of 100 µM.
7. Allow the peptides to dissolve at room temperature, then gently triturate several times using a pipette. Avoid introducing air bubbles.
8. Label 3 test tubes as follows:
 - tube 1: water only no peptide control
 - tube 2: phosphopeptide
 - tube 3: non-phosphopeptide
9. Prepare 2x peptide stock solutions (2.66 µM) or water control by pipetting the following:
 - tube 1: water control stock: 0.973 mL buffer (TBS or PBS plus blocking protein) plus 27 µL water.
 - tube 2: phosphopeptide 2x stock: 0.973 mL buffer (TBS or PBS plus blocking protein) plus 27 µL reconstituted (100 µM) phosphopeptide.
 - tube 3: non-phosphopeptide 2x stock: 0.973 mL buffer (TBS or PBS plus blocking protein) plus 27 µL reconstituted (100 µM) non-phosphopeptide.
10. Apportion unused reconstituted peptide solutions into working aliquots and store at -20°C for future use.
11. Pipette 1 mL of the 2x antibody stock into each of the tubes marked 1, 2, and 3. The tubes should be incubated for 30 minutes at room temperature with gentle rocking.
12. The pre-incubated antibody in each of the three tubes is then ready for use. Pipette the contents of each tube onto the three identical test samples.

For Western blotting strips:

 - ◆ Incubate these strips for 2 hours at room temperature, followed by several washes to remove unbound antibody.
 - ◆ Transfer each strip to a new solution containing a labeled secondary antibody (example goat anti-rabbit IgG-alkaline phosphatase conjugate).
 - ◆ Remove unbound secondary antibody by thorough washing and develop bands.

The signals obtained with antibody incubated with “(1) water only no peptide control”, which represents the maximum signal, and the signals obtained with “(2) phosphopeptide” and “(3) non-phosphopeptide” are readily compared under these conditions.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

This antibody is manufactured under a licensed process covered by Patent # 5, 599, 681.

PI44744

(Rev 11/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.